A nontumorigenic variant of FGF19 treats cholestatic liver diseases.

PubWeight™: 1.64‹?› | Rank: Top 3%

🔗 View Article (PMID 25080475)

Published in Sci Transl Med on July 30, 2014

Authors

Jian Luo1, Brian Ko2, Michael Elliott2, Mei Zhou2, Darrin A Lindhout2, Van Phung2, Carmen To2, R Marc Learned2, Hui Tian2, Alex M DePaoli2, Lei Ling1

Author Affiliations

1: NGM Biopharmaceuticals Inc., 630 Gateway Boulevard, South San Francisco, CA 94080, USA. lling@ngmbio.com jluo@ngmbio.com.
2: NGM Biopharmaceuticals Inc., 630 Gateway Boulevard, South San Francisco, CA 94080, USA.

Articles citing this

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65

Bile acids as metabolic regulators. Curr Opin Gastroenterol (2015) 1.03

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov (2015) 0.90

Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis (2015) 0.86

Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis. Semin Cell Dev Biol (2015) 0.86

Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Front Endocrinol (Lausanne) (2015) 0.83

Recent advances in understanding and managing cholestasis. F1000Res (2016) 0.79

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. Front Endocrinol (Lausanne) (2015) 0.77

Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064. Toxicol Appl Pharmacol (2016) 0.76

Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors. Biomed Res Int (2016) 0.75

Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol (2017) 0.75

Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol (2017) 0.75

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism. Ann Transl Med (2015) 0.75

Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation. PLoS One (2017) 0.75

Liver: a variant of FGF19 protects the liver from cholestatic injury without inducing cancer. Nat Rev Gastroenterol Hepatol (2014) 0.75

Bile Acid Uptake Transporters as Targets for Therapy. Dig Dis (2017) 0.75

Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis (2017) 0.75

Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One (2017) 0.75